Unknown PHASE2 INTERVENTIONAL 2-arm NCT04429763

Safety and Efficacy of Mesenchymal Stem Cells in the Management of Severe COVID-19 Pneumonia (CELMA)

Safety and Efficacy of Mesenchymal Stem Cells in the Management of Severe COVID-19

Sponsor: Fundación Universitaria de Ciencias de la Salud

Conditions COVID-19

Interventions Placebo Umbilical cord derived mesenchymal stem cells

Updated 5 times since 2020 Last updated: Jun 10, 2020 Started: Jul 31, 2020 Primary completion: Sep 30, 2020 Completion: Nov 30, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04429763, this PHASE2 trial focuses on COVID-19 and remains ongoing. Sponsored by Fundación Universitaria de Ciencias de la Salud, it has been updated 5 times since 2020, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jul 2022 — Jul 2024 [monthly]

Unknown Status PHASE2

Status: Not Yet Recruiting → Unknown Status
Jan 2021 — Jul 2022 [monthly]

Not Yet Recruiting PHASE2
Jul 2020 — Jan 2021 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Fundación Universitaria de Ciencias de la Salud
Hospital Infantil Universitario de San Jose
Hospital de San Jose
Trustem

Data source: Trustem

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.